Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Something material being released at 4:30 - only reason to have this call is to release something positive
Moving forward:
1)Amarin needs to go balls to wall with DTC, and sell sell sell into appeals case.
TK: Yea - the hell with FDA approval....hide behind first amendment at this point
2)Screw getting Europe partner.
TK: Partner
3)Forget all “future investor” conferences.
TK: AGREE
4)Buyback stock.
TK: AGREE
5)Get new members on Board of Directors
TK: AGREE
Thoughts?
People sitting around thinking -
“wow, maybe I made a mistake and got scared yesterday.....maybe this is over blown....I better get back in so I can recoup my losses from the ride down”
Once people see the full potential globally and understand we are way under valued WITH the recent legal shenanigans - we move up
I think insurance won’t care when it’s a fraction of the cost.....they will look the other way especially when they know it’s exact same product
I love that idea
The issue is that Drs will know their is a generic version and just prescribe off-label.....it’s really as simple as that.
Some may not - but that will be the exception
Amarin strongly disagrees with the ruling and will vigorously pursue all available remedies, including an appeal of the Court’s decision and a preliminary injunction pending appeal to, if an ANDA is approved by FDA, prevent launch of generic versions of VASCEPA in the United States,” said John F. Thero, president and chief executive officer of Amarin.
“At Amarin, we have a strong balance sheet with capacity and flexibility, and we plan to fight to protect our VASCEPA franchise for the benefit of our patients, physicians, the broader healthcare community and our investors. We believe we are favorably situated to obtain an injunction against generic launch pending appeal, subject to our posting a bond to secure generics’ lost profits in the event that generics prevail on appeal. As we work to take all legal actions necessary to defend and protect our intellectual property, we will continue to press forward with our educational and promotional efforts for VASCEPA in treating indicated patients at high risk of cardiovascular events, such as heart attack and stroke. After we determine the outcome of our effort to prevent a generic launch (if an ANDA approval is obtained), we expect to provide an update on how we would adjust certain promotional activities for VASCEPA in the United States.”
Geographies outside the United States in which VASCEPA is sold and under regulatory review are not subject to this litigation and judgment. No generic litigation is pending outside the United States. VASCEPA remains available by prescription in Canada, Lebanon and the United Arab Emirates. In Canada, VASCEPA has the benefit of eight years of data protection afforded through Health Canada (until the end of 2027), in addition to separate patent protection with expiration dates that could extend into 2039. Amarin, together with its commercial partners in select geographies, is pursuing additional regulatory approvals for VASCEPA in the European Union, China and the Middle East. Ten to eleven years of market protection is anticipated due to regulatory exclusivity in the European Union subject to pending VASCEPA approval expected later this year, in addition to pending patent protection that could extend into 2033.
We lose - WOW
$7 on a Loss
$20 on win
Sound about right?
Tomorrow could be the day
Today’s ACC AMRN Sessions
Session 1263-090 – “REDUCE-IT Eligibility and Preventable First and Total Cardiovascular Events in the US Population: An Analysis of the National Health and Nutrition Examination Survey (NHANES)” – Nathan D. Wong, Wenjun Fan, Peter P. Toth, Craig Granowitz, Sephy Philip – presented March 29, 10:00-10:45 a.m. Central U.S. Time
Session 1313-090 – “Residual Cardiovascular Risk in U.S. Veterans with Moderately-Elevated Baseline Triglycerides Across the Cardiovascular Risk Spectrum” – Sarah Leatherman, Ryan E. Ferguson, Cynthia Hau, Craig Granowitz, Kelly Harrington, Sephy Philip, Peter P. Toth, Deepak L. Bhatt, William E. Boden – presented March 29, 12:30-1:15 p.m. Central U.S. Time
Session 1364-202 – “Eicosapentaenoic Acid Inhibits High Density Lipoprotein (HDL) Oxidation in a Synergistic Manner in Combination with Atorvastatin In Vitro” – R. Preston Mason, Samuel C. R. Sherratt – presented March 29, 3:45-4:30 p.m. Central U.S. Time
Session 1309-177 – “Association of Inflammatory Markers with Baseline Coronary Plaque Volumes by Coronary Computed Tomography Angiography (CCTA) from EVAPORATE (Effect of Vascepa on Improving Coronary Atherosclerosis in People with High Triglycerides Taking Statin Therapy) Trial” – Suvasini Lakshmanan, Chandana Shekar, Suraj Dahal, Afiachukwu Onuegbu, April Kinninger, Andrew Cai, Vahid Rezvanizadeh, Ilana Golub, Divya Birudaraju, Lavanya Cherukuri, Sajad Hamal, Christopher Dailing, Ferdinand Flores, Sion K. Roy, John R. Nelson, Matthew J. Budoff – presented March 29, 12:30-1:15 p.m. Central U.S. Time
BigHen - I was just pondering the exact same question.
Today’s AMRN ACC.20/WCC Sessions
Session 1161-128 – “Cost-effectiveness of Icosapent Ethyl in US REDUCE-IT Patients” – William S. Weintraub, Deepak L. Bhatt, Zugui Zhang, Cheng Zhang, Sarahfaye Dolman, William E. Boden, P. Gabriel Steg, Michael Miller, Eliot A. Brinton, Jordan B. King, Adam P. Bress, Terry A. Jacobson, Jean-Claude Tardif, Christie M. Ballantyne, Paul Kolm – presented March 28, 12:30-1:15 p.m. Central U.S. Time
Session 1212-205 – “Eicosapentaenoic Acid Inhibits Oxidation of Very Large Density Lipoproteins (VLDL) in a Dose-Dependent Manner over Time as Compared to Docosahexaenoic Acid In Vitro” – R. Preston Mason, Samuel C. R. Sherratt – presented March 28, 3:45-4:30 p.m. Central U.S. Time
Session 1158-161 – “Association of HDL Subclasses with Baseline Coronary Plaque Burden By Coronary Computed Tomography Angiography (CCTA) from EVAPORATE (Effect of Vascepa on Improving Coronary Atherosclerosis in People with High Triglycerides Taking Statin Therapy) Trial” – Suvasini Lakshmanan, Chandana Shekar, Suraj Dahal, Afiachukwu Onuegbu, April Kinninger, Andrew Cai, Divya Birudaraju, Ilana Golub, Vahid Rezvanizadeh, Christopher Dailing, Ferdinand Flores, Sajad Hamal, Sion K. Roy, John R. Nelson, Matthew J. Budoff – presented March 28, 12:30-1:15 p.m. Central U.S. Time
March Madness 2021
Biobillionaire and rafunrafun
Where is Sam?
90k in the midst of COVID-19 ....interesting
But the Lovaza #’s - infuriate me
3 Business days in March left!
Bullish Close
Very informative - thanks for sharing.
But that is probably going to be delayed due to Europe being shut down?
Day 120 Opinion by EMA
That’s DU this month as well...right?
You see what I did there
Significant volume since 3:00
I feel like the last 8 years of my life is centered around refreshing some site waiting on Amrn news that will materially impact my life.
So hedge funds have an intern sitting in corner hitting refresh on PACER with an open browser(s) with their buy/sell orders ready to go
Procedure question
Do the attorneys get prior notification before PACER is updated.....or do they find out when the rest of us do?
Will Amrn halt stock?
Captain DU Obvious: 4 calendar days left in March
DU
EOM
Awesome - thanks for info
Of note
Clerk’s Office
TheClerk’sOfficewillbeclosedtothepublicbeginningMarch20,2020.This closure does not affect any filings. Attorneys and pro se parties may continue to file documents with the Court. All deadlines will remain in full effect unless otherwise ordered by the presiding judge.
Do we even know if Nevada court system is in a ‘work-from-home’ state or is the court system shut down?
This could impact Judge DU’s ability to send out a judgement?
How so?
DU it because it’s the right thing to do
DU it for my kids college fund
DU it for my 401k balance
COME ON DU - I want to know my future
JUDGE DU
6 business days in March left Dr. Du!
It’s AMRN’s week - We are DU
Come on verdict
OK - Something is up